Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
Pfizer(PFE) stock is priced at $25.88, giving the company a market capitalization of 147.15B. It carries a P/E multiple of 15.07 and pays a dividend yield of 6.7%.
As of 2025-12-13, Pfizer(PFE) stock has fluctuated between $25.72 and $26.04. The current price stands at $25.88, placing the stock +0.6% above today's low and -0.6% off the high.
Pfizer(PFE) shares are trading with a volume of 51.6M, against a daily average of 45.55M.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.69 and a 52-week low of $20.92.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.69 and a 52-week low of $20.92.
PFE News
It's time for investors to give up on the telemedicine leader. Telemedicine leader Teladoc Health (TDOC 0.92%) has been struggling for several years. The compa...
Morgan Stanley (MS) has issued a less optimistic outlook on the performance of the shares of American pharmaceutical giant Pfizer (PFE) for 2026. Claim 50% Off...
Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term. Even very well-run...
Analyst ratings
57%
of 28 ratingsMore PFE News
Morgan Stanley lowered the firm’s price target on Pfizer (PFE) to $28 from $32 and keeps an Equal Weight rating on the shares. The firm expects many of the poli...
Pfizer Inc. recently entered an exclusive global collaboration and license agreement with YaoPharma for YP05002, an oral GLP-1 receptor agonist in Phase 1 for c...
Pfizer (PFE) closed at $27.41 in the latest trading session, marking a +1.59% move from the prior day. The stock's change was more than the S&P 500's daily gain...
Pfizer Inc. (NYSE:PFE) on Wednesday shared detailed results from the Phase 3 HER2CLIMB-05 trial of Tukysa (tucatinib) as part of an investigational first-line m...
Pfizer PFE announced that it is in-licensing exclusive global rights to develop, manufacture and commercialize YP05002, an oral small molecule GLP-1 receptor ag...
Johnson & Johnson JNJ and Pfizer PFE are both healthcare leaders with large drug portfolios and diversified revenue streams, making them direct peers in the blu...
Key Points Pfizer is one of the world's largest drugmakers. It has long managed to produce new blockbuster drugs to replace drugs losing patent protection. I...